


# France

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009		2012		2015		2018
International units per capita	Factor VIII	5.75	▲	7.19	▼	0.00	▲	7.05
	Factor IX	0.87	▲	1.04	▼	0.00	▲	1.21
Organisation of care	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	Yes		Yes		Yes		Yes
	Number of groups in decision-making on haemophilia care	3		3		3		3
	Number of groups choosing haemophilia treatment products	3		3		3		3
	National Tender for procurement of factor concentrates	No		No		No		No
Treatment regimens	Home Treatment	Yes		Yes		Yes		Yes
	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
	Treatment delivered to the patient's home	No		No		No		Some
	Prophylaxis treatment availability	Yes		Yes		Yes		Yes
	Children currently on prophylaxis (%)	51-75%	▲	76-100%		76-100%		76-100%
	Adults currently on prophylaxis (%)	26-50%		26-50%		26-50%	▲	51-75%
Access to ITI (% of people with inhibitors)	100%	▼	26-50%	▲	100%		100%	
Access to specialist services	Emergency medicine and acute surgery	Yes		Yes				Yes
	Paediatrics	Yes		Yes				Yes
	Infectious disease specialists (especially HIV)	Yes		Yes				Yes
	Hepatology	Yes		Yes				Yes
	Rheumatology	Yes		Yes				Yes
	Orthopaedics	Yes		Yes				Yes
	Physiotherapy	Yes		Yes				Sometimes
	Dentistry	Yes		Yes				Yes
	Obstetrics and Gynaecology	Yes		Yes				Yes
	Genetics	Yes		Yes				Yes
	Social and psychological support	Yes		Yes				Sometimes
	Pain management	Yes		Yes				Sometimes
	General surgery	Yes		Yes				Yes
	Urology	Yes		Yes				Yes
Share of Expected Bleeding Disorder Prevalence	Haemophilia A	61%	▲	72%	▲	81%	▲	91%
	Haemophilia B	43%	▲	52%	▲	60%	▲	69%
	von Willebrand Disease	1%	▲	2%	▲	3%	▲	3%
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always		Always		Always		Always
	Recombinant factor concentrate	Always		Always		Always		Always
	Plasma	Never		Never		Never		Never
	Cryoprecipitate	Never		Never		Never		Never
VWD replacement therapy	Plasma-derived factor concentrate	Always		Always				Always
	DDAVP	Always		Always				Always
	Plasma	Never		Never				Never
	Cryoprecipitate	Never		Never				Never